Tactiva Therapeutics

Tactiva Therapeutics is developing potent cancer immunotherapies using a dual T cell receptor (TCR) approach. Current cell therapy strategies in immunotherapy focus primarily on developing anti-tumor CD8 T cell responses - Tactiva on the other hand are utilizing a unique class of CD$ T cells that not only enhance the anti-tumor function of CD8 T cells, but also exhibit a capacity to directly target the tumor cells. To achieve this Tactiva is identifying a library of TCRs from both CD8 and CD4 T cells to use in their next-generation adoptive T cell therapy platform. Besides using mature T cells for their adoptive cell therapy, Tactiva’s platform also uses hematopoietic stem cells for deploying the TCRs so that they can generate a long-term source of anti-tumor T cells.

Jobs: